Aurinia Pharmaceuticals (AUPH) EBITDA (2019 - 2026)

Aurinia Pharmaceuticals' EBITDA history runs 8 years deep, the most recent figure standing at $41.4 million for Q1 2026.

• Quarterly EBITDA rose 89.6% year-over-year to $41.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $124.5 million (up 309.33% YoY) and the FY2025 annual result came in at $104.9 million, up 2338.4% from the prior year.
• EBITDA was $41.4 million for Q1 2026 at Aurinia Pharmaceuticals, up from $33.2 million in the prior quarter.
• Across five years, EBITDA topped out at $41.4 million in Q1 2026 and bottomed at -$37.9 million in Q1 2022.
• A 5-year average of -$3.6 million and a median of -$9.5 million in 2022 frame the typical range for EBITDA.
• Annual changes were most pronounced in 2023 — EBITDA sank 71.21% — and 2025, when it surged 2091.55%.
• Aurinia Pharmaceuticals' EBITDA stood at -$28.1 million in 2022, then decreased by 5.6% to -$29.7 million in 2023, then jumped by 94.38% to -$1.7 million in 2024, then jumped by 2091.55% to $33.2 million in 2025, then rose by 24.62% to $41.4 million in 2026.
• Business Quant data shows AUPH's EBITDA at $41.4 million in Q1 2026, $33.2 million in Q4 2025, and $29.7 million in Q3 2025.